[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621234":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Atom Therapeutics Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ABP-671","EXPERIMENTAL",null,[13],"Drug: ABP-671 plus allopurinol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","ABP-671 plus allopurinol","All subjects undergo three sequential 7-day periods:\n\nPeriod 1 (Day 1-7): Allopurinol；\n\nPeriod 2 (Day 1-7): Allopurinol Plus ABP-671；\n\nPeriod 3 (Day 1-7): ABP-671；",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"MaoE Sun","CONTACT","13914017855","mao.e.sun@atombp.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Wakefield Clinical Research","RECRUITING","Cary","North Carolina","27560","United States",{"type":35,"coordinates":36},"Point",[37,38],-78.78112,35.79154,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":11,"phoneExt":11,"email":11},"Xiaohuan Li, MD","PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100621234",false,"NCT07367971","Drug-Drug Interaction Study of ABP-671 in Gout Patients","Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients","Inclusion Criteria:\n\n* Adults 18-75 years with clinical diagnosis of gout.\n* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.\n* Cohort N: Normal renal function.\n* Cohort R: Moderate renal impairment.\n\nExclusion Criteria:\n\n* Clinically significant hepatic impairment.\n* History of Allopurinol hypersensitivity.\n* Pregnancy or breastfeeding.","ALL","18 Years","75 Years",{"count":56,"type":57},20,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.",[63,64,65],"Gout Chronic","Gout","DDI (Drug-Drug Interaction)",[67,63,9],"gout","2026-04-12",{"date":70,"type":71},"2026-04-14","ACTUAL",{"date":73,"type":71},"2026-01-23",{"date":75,"type":57},"2026-08-31",{"name":5,"class":6},1]